01—Abstract
Summary
Summary of the 10-K filed February 27, 2013. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation's 2012 10-K filing reveals a company with robust revenue growth and diverse product segments, including Reconstructive, MedSurg, and Neurotechnology and Spine.
In 2012, the company generated $8.66 billiona in net sales and $1.30 billion in net earnings. The Reconstructive segment, primarily focused on joint replacements, showed steady growth, while MedSurg, encompassing surgical equipment and systems, also saw increases. The Neurotechnology and Spine segment experienced significant growth, largely driven by strategic acquisitions that expanded its product offerings in neurovascular and spinal devices.
The company highlights its commitment to innovation, with ongoing research and development investments, and strategic acquisitions to bolster its portfolio. However, Stryker also faces several risks, including potential impacts from healthcare reform legislation, particularly the 2.3%b medical device excise tax, pricing pressures due to cost containment measures, and significant legal and regulatory risks, including ongoing product liability lawsuits and investigations. Despite these challenges, Stryker demonstrated strong operating cash flow and maintained a healthy liquidity position.
02—Key points
Key Highlights
- Stryker reported 2012 net sales of $8.66 billion, a 4.2% increase over 2011, with net earnings of $1.30 billion.
- The company's three reportable segments – Reconstructive, MedSurg, and Neurotechnology and Spine – all contributed to sales growth, with Neurotechnology and Spine showing the strongest percentage increase.
- Significant acquisitions in 2011 and 2012, including Neurovascular, Orthovita, Memometal, and Surpass Medical, expanded Stryker's product lines, particularly in the Neurotechnology and Spine segment.
- Research, development, and engineering expenses remained a consistent percentage of sales (around 5.4%), reflecting ongoing investment in innovation.
- Stryker faces significant legal and regulatory risks, including a voluntary recall of its Rejuvenate and ABG II hip stems, leading to an estimated loss of $190-$390 million, and an ongoing investigation related to the OtisKnee device.
- The company maintained a strong liquidity position with $4.29 billion in cash, cash equivalents, and marketable securities at the end of 2012.
- Future growth may be influenced by the upcoming acquisition of Trauson Holdings Company Limited, targeting the Chinese orthopaedic market.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2012, Stryker Corp kept $0.15.
- Revenue$8.66B100.0%
- Cost of revenue−$2.78B32.1%
- Gross profit$5.88B67.9%
- Operating costs−$4.13B47.8%
- Operating income$1.74B20.1%
- Interest, other & tax−$443.0M5.1%
- Net income$1.30B15.0%
Where FY2012 revenue went
$8.66B- SG&A: $3.37B, 39% of revenue
- Cost of revenue: $2.78B, 32% of revenue
- Net income: $1.30B, 15% of revenue
- R&D: $471.0M, 5.4% of revenue
- Other operating costs: $297.0M, 3.4% of revenue
- Interest, other & tax: $443.0M, 5.1% of revenue
Kept 15% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2012filed February 27, 2013Financial Statements
FY2012 against FY2011
| Line item | FY2012FY2011 | Change |
|---|---|---|
| Revenue | $8.66B$8.31B | +4.2% |
| Cost of Revenue | $2.78B$2.81B | −1.1% |
| Gross Profit | $5.88B$5.50B | +6.9% |
| R&D Expenses | $471.00M$462.00M | +1.9% |
| SG&A Expenses | $3.37B$3.15B | +6.9% |
| Operating Expenses | $4.13B$3.81B | +8.5% |
| Operating Income | $1.74B$1.69B | +3.3% |
| Interest Expense | $63.00M$56.00M | +12.5% |
| Net Income | $1.30B$1.34B | −3.5% |
| EPS (Basic) | $3.41$3.48 | −2.0% |
| EPS (Diluted) | $3.39$3.45 | −1.7% |
| Shares Outstanding (Basic) | 380.60M386.50M | −1.5% |
| Shares Outstanding (Diluted) | 383.00M389.50M | −1.7% |
05—Questions
Frequently Asked Questions
What were the primary drivers of Stryker's revenue growth in 2012?
Stryker's revenue growth in 2012 was driven by a combination of increased unit volume across its segments, particularly in Neurotechnology and Spine, Instruments, and Trauma and Extremities. Strategic acquisitions also played a significant role in expanding the company's product portfolio and market presence. However, the growth was partially offset by softness in European markets and pricing pressures.
What are the most significant risks and challenges facing Stryker, as highlighted in the filing?
Key risks include the impact of healthcare reform in the U.S., specifically the 2.3% medical device excise tax effective January 2013, and potential pricing pressures due to cost containment measures. The company is also subject to significant legal and regulatory risks, including product liability claims stemming from hip stem recalls (Rejuvenate and ABG II) and ongoing investigations. Competition and the need for continuous innovation are also highlighted as ongoing challenges.
How did Stryker manage its financial position and liquidity in 2012?
Stryker demonstrated strong financial management. Operating cash flow increased by 15.6% to $1.66 billion in 2012, supported by effective inventory management. The company maintained a substantial cash and equivalents balance of $4.29 billion, and secured a $1 billion unsecured revolving credit facility, ensuring ample liquidity to support operations, investments, and potential acquisitions. Dividend payments also increased, reflecting confidence in financial stability.
What is the significance of the company's segment performance in 2012?
The Neurotechnology and Spine segment showed the most significant growth, increasing 9.2% year-over-year, driven by acquisitions and strong product demand. The Reconstructive segment, a core business, grew by 3.1%, bolstered by trauma products and a competitor's product recall. MedSurg also contributed with a 3.3% increase, led by Instruments and reprocessed medical devices. This diversified performance across segments indicates a balanced business model.
06—Continue